Skip to main content
Clinical Trials/NCT02938078
NCT02938078
Terminated
Not Applicable

Ocular Comfort and Markers of Inflammation in Subjects Undergoing Lid Hygiene Therapy

Minnesota Eye Consultants, P.A.1 site in 1 country14 target enrollmentOctober 2016
ConditionsBlepharitis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Blepharitis
Sponsor
Minnesota Eye Consultants, P.A.
Enrollment
14
Locations
1
Primary Endpoint
Change in Severity of Markers of Inflammation
Status
Terminated
Last Updated
5 years ago

Overview

Brief Summary

The primary study objectives are: to evaluate (1) the change in ocular discomfort at 30 days and (2) the change in signs and symptoms of ocular surface disease in demodex-positive subjects beginning the use of Avenova.

Detailed Description

This is a prospective study of subjects who have been diagnosed with bilateral demodex blepharitis. Qualified symptomatic eyes will be randomized and monitored for 30 days; one eye will undergo Avenova treatment twice daily and one eye will not undergo any study treatment.

Registry
clinicaltrials.gov
Start Date
October 2016
End Date
August 24, 2018
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject signed and dated a IRB-approved informed consent document
  • Mild or greater Demodex (minimum 15 observable mites in six lashes)
  • Score of 20 or more on the OSDI Questionnaire
  • Score of 20 or more on the Eyelid Inflammation Questionnaire

Exclusion Criteria

  • Currently enrolled in another prospective research study
  • Unable to attend two follow-up visits over 30 days
  • Current allergic conjunctivitis of the cornea, conjunctiva, or eyelid in either eye
  • Prior ocular trauma where surgery was indicated
  • Prior corneal transplant in either eye
  • Any ocular surgery within the past six months
  • Abnormal corneal scarring, erosions, or Stevens-Johnson syndrome
  • Anticipation of ocular surgery within the next 30 days
  • Non-English speaking
  • Pregnant, nursing, or expect to become pregnant within the next 30 days

Outcomes

Primary Outcomes

Change in Severity of Markers of Inflammation

Time Frame: 30 days

Clinical parameters include meibomian gland evaluation

Change in Severity of Markers of Inflammation using tear osmolarity.

Time Frame: 30 days

Clinical parameters include tear osmolarity.

Change in Ocular Discomfort

Time Frame: 30 days

Change in ocular discomfort based on scores from Ocular Surface Disease Index questionnaire. Scored on a scale of 0-100, with higher scores indicating greater disability.

Study Sites (1)

Loading locations...

Similar Trials